Key result
Targeting nonstructural proteins such as the viral protease, RNA-dependent RNA polymerase, and methyltransferases represents a promising strategy for developing novel antiviral drugs against SARS-CoV-2.
Why the study?
Outbreaks of SARS-CoV, MERS-CoV, and SARS-CoV-2 have caused high pathogenicity and mortality, making the acceleration of novel antiviral drug development a pressing need.
This review outlines potential molecular targets in human coronaviruses, such as 3C-like protease and papain-like protease, to guide the structure-based design and development of novel antiviral drugs against SARS-CoV-2.
May inform structure-based design of coronavirus protease inhibitors; leaves open clinical translation for SARS-CoV-2.
Outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 have produced high pathogenicity and mortality rates in human populations. However, to meet the increasing demand for treatment of these pathogenic coronaviruses, accelerating novel antiviral drug development as much as possible has become a public concern. Target-based drug development may be a promising approach to achieve this goal. In this review, the relevant features of potential molecular targets in human coronaviruses (HCoVs) are highlighted, including the viral protease, RNA-dependent RNA polymerase, and methyltransferases. Additionally, recent advances in the development of antivirals based on these targets are summarized. This review is expected to provide new insights and potential strategies for the development of novel antiviral drugs to treat SARS-CoV-2 infection.
No takes yet. Share an insight, caveat, or question.
Its licence doesn't allow us to show a copy here.
Liu et al. (2020) conducted a review in SARS-CoV-2 infection. Antiviral drugs targeting nonstructural proteins was evaluated. Targeting nonstructural proteins such as the viral protease, RNA-dependent RNA polymerase, and methyltransferases represents a promising strategy for developing novel antiviral drugs against SARS-CoV-2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: